Evidence map›Paper›PMID 40973816›Full record

ArticleNature biomedical engineering2026

Spatial profiling of gene editing by in situ sequencing in mice and macaques.

Sharan Janjuha, Tatjana Haenggi, Thomas C Chamberlain, Tanja Rothgangl, Lucas Kissling, Maria Wilhelm, Nicolas Mathis, Desiree Boeck, Kim Marquart, Eleonora Ioannidi and 7 more

Abstract read
In one paragraph

Article in Nature biomedical engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Sharan Janjuha *Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland. sharan.janjuha@pharma.uzh.ch.ORCID http://orcid.org/0000-0002-5910-2912
Tatjana Haenggi *Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.
Thomas C ChamberlainAcuitas Therapeutics, Vancouver, British Columbia, Canada.ORCID http://orcid.org/0000-0002-3030-6065
Tanja RothganglInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.
Lucas KisslingInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0002-4989-0695
Maria WilhelmInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0009-0002-9935-5161
Nicolas MathisInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0002-4051-8344
Desiree BoeckInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.
Kim MarquartInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.
Eleonora IoannidiInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.
Woohyun J MoonAcuitas Therapeutics, Vancouver, British Columbia, Canada.ORCID http://orcid.org/0009-0001-1395-823X
Hiromi MuramatsuDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-1544-1493
Máté VadovicsDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0001-9028-987X
Norbert PardiDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-1008-6242
Sean C SempleAcuitas Therapeutics, Vancouver, British Columbia, Canada.
Ying K TamAcuitas Therapeutics, Vancouver, British Columbia, Canada.ORCID http://orcid.org/0000-0002-4083-5251
Gerald SchwankInstitute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland. schwank@pharma.uzh.ch.ORCID http://orcid.org/0000-0003-0767-2953

Funding

Project 4: Computational panbetaCoV immunogen designP01AI158571 · NIAID · DUKE UNIVERSITY · PI HENDERSON, RORY · 2021 to 2023
$28.0M
Understanding antibody responses and defining correlates of protection for endemic and pandemic coronavirus strainsP01AI172531 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Florian Krammer · 2023 to 2026
$12.5M
Lipid nanoparticles as novel adjuvants inducing effective T follicular helper cell and humoral immune responsesR01AI153064 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Michela Locci, Norbert Pardi · 2020 to 2026
$4.2M
NIAID NIH HHS P01 AI158571NIAID NIH HHS P01 AI172531NIAID NIH HHS R01 AI153064Swiss National Science Foundation 185293
6 · The paper itself

Abstract

Base and prime editing technologies precisely install defined nucleotide edits in both dividing and non-dividing cells, offering potential for correcting pathogenic mutations directly in organisms. However, to fully leverage their therapeutic potential, accurately measuring editing rates with high spatial resolution is crucial. Here we use imaging-based in situ sequencing (ISS) to map base and prime editing events within native tissues. We establish and validate this technology in mouse brains treated with intein-split adenine base editors or prime editors delivered via adeno-associated viral vectors. We next apply ISS in the liver of mice and macaques treated with adenine base editors encoded on lipid nanoparticle-encapsulated mRNA and guide RNA (RNA-LNP). Effective editing was observed across all metabolic zones of liver lobules. Moreover, in experiments where repeated doses of RNA-LNP are administered, the initial dose does not affect the editing efficiency and distribution of the subsequent dose. Our results demonstrate how ISS can visualize gene editing events in vivo and suggest that base editor delivery using RNA-LNP could be used to address a wide spectrum of metabolic liver diseases.

Indexed as

Gene EditingAnimalsBrainCRISPR-Cas SystemsDependovirusLipidsLiverMacacaMaleMiceMice, Inbred C57BLNanoparticlesRNA, Guide, CRISPR-Cas SystemsRNA, MessengerLipidsRNA, Guide, CRISPR-Cas SystemsRNA, Messenger

Identifiers

PMID40973816
PMCPMC7618712

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.